Le Lézard
Classified in: Health
Subject: SVY

Japan Pharmaceutical Firm Sales Practices Report 2018: Current Sales Activities, Regulations, Issues, and Suggested Methodologies


DUBLIN, Sept. 21, 2018 /PRNewswire/ --

The "Japanese Sales Practices at Pharmaceutical Firms - 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This report discusses about the general sales practices at pharmaceutical firms in Japan. The readers will understand about the current sales activities, regulations, issues, and suggested methodologies.

The number of MR in Japan in 2017 was 62,433, decreased by 1.2% from that of previous year. While Until 2016, CSO had been driving the growth of MR organization until 2016, we saw huge drop in 2017, as it couldn't hold the pool of MR any longer, due to the decreased demand from pharma.

The number of MR in Japan is yet too large. Among developed nations, Japan follows the United States in terms of number of MR. Importantly, when we look at the number of physicians per number of MR, Japan has below five (physicians/MR), while the United States has approximately thirteen. We see considerable gap and an outstanding issue in terms of productivity.

As foreign firms expand their businesses in Japan, now over half of top 10 companies who have largest MR organization are non-Japanese pharma companies. Now, pharma companies have been facing the needs of cost reduction, due to the recent slow sales and shrinking domestic pharma market.

Pharmaceutical firms' sales-centric approach had been criticized for a long time, but no practical measures were not taken, as medical institutions and physicians relied on the fi-nancial contribution done by pharma companies. The Diovan scandal that occurred in 2013 finally changed the situation surrounding MR dramatically. It pushed the back of MHLW, Ministry of Health, Labor, and Welfare, to create the new regulation onto clinical researches, which was implemented in April 2018. Academia is now required to follow the similar processes of clinical studies.

The Diovan case also shed the light on the un-productivity of MR to the public. Now pharma companies have been very eager to have MSL and medical affairs team take over MR's primary function. Accordingly, pharma companies have started to decrease the number of MR. CSOs are also facing the difficult phase, due to the decreased needs of MR in pharma. There is no question that going forward, a major shift will be made to-wards so-called e-MR services deployed over the Internet, such as MR-kun provided by M3.

Key Topics Covered:

1. Summary

2. Scope Discussed

3. Medical Representative

4. Regulations Concerning the Sale of Pharmaceuticals

5. Number of MR

6. Number of MR by Company

7. Is the number of MR in Japan reasonable?

8. Why Are There So Many MRs in Japan?

9. Financial Contributions to Medical Institutions, Universities, and Physicians

10. Dramatic Change around MR

11. Why non-Japanese Pharma Followed Japanese Traditional Business Practices?

12. Declining MR's Presence

13. Future Outlook

For more information about this report visit

https://www.researchandmarkets.com/research/cbsmk8/japan?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 15:44
Late yesterday the United States District Court for the Northern California ruled that CVS acted intentionally under the "deliberate indifference" standard when it implemented a drug program that discriminates against people living with HIV....

at 15:33
Alameda Health System needs help identifying a patient who arrived at the Wilma Chan Highland Hospital Campus on March 15, 2024, without identification....

at 15:20
Vayiz, an exciting new startup in innovative AI-driven medical imaging solutions, today announced the launch of its groundbreaking product, PTLC - Mark 1. This advanced medical diagnosis software utilizes state-of-the-art artificial intelligence to...

at 15:00
The Flowery, the leading name in the Florida medical cannabis industry renowned for its commitment to the highest quality and authentic experiences, proudly announces its unique collaboration with Udonis Haslem, a 3-time NBA Champion and legendary...

at 14:50
American Skin Association (ASA) is thrilled to announce that it has received Candid's eminent 2024 Platinum Seal of Transparency and the coveted Four-Star Rating from Charity Navigator. Candid (formerly Guidestar & Foundation Center) is the world's...

at 14:48
Loyal, the San Francisco-based company dedicated to improving the health and longevity of dogs, and Prelude, the leading animal health-focused electronic data capture (EDC) system for clinical research, are proud to announce their strategic...



News published on and distributed by: